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Abstract: Hutchinson–Gilford Progeria Syndrome and Werner syndrome, also known as 
childhood- and adulthood-progeria, respectively, represent two of the best characterized human 
progeroid diseases with clinical features mimicking physiological aging at an early age. The 
discovery of their genetic basis has led to the identification of several gene mutations leading to 
a spectrum of progeroid phenotypes ranging from moderate and mild–severe to very aggressive 
forms. In parallel, the creation of disease registers and databases provided available data for 
the design of relatively large-scale epidemiological studies, thereby allowing a better under-
standing of the nature and frequency of the premature aging-associated signs and symptoms. 
The aim of this article is to review the most recent findings concerning the epidemiology of 
premature aging disorders, their genetic basis, and the most recent reports on the frequency of 
associated diseases.
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Introduction
Hutchinson–Gilford Progeria Syndrome (HGPS) and Werner syndrome (WS) are two 
of the best characterized human progeroid diseases with clinical features mimicking 
physiological aging at an early age, the first being referred as to childhood progeria, 
and the latter as progeria of adulthood.1 An increasing number of intermediate prog-
eroid phenotypes, known as atypical progeroid syndromes, atypical HGPS, or atypical 
WS, have been described.1 The aim of this review article is to describe the most recent 
findings concerning the epidemiology of premature aging disorders, their genetic basis, 
and the most recent reports on the frequency of associated diseases.
Hutchinson–Gilford Progeria Syndrome
HGPS is an extremely rare genetic disorder affecting about one per four to eight million 
live births.2 More precisely, the reported prevalence rate of the disease is one in 
eight million births, but if unreported or misdiagnosed cases are taken into account, 
the estimated birth prevalence is one in four million.2
According to the Progeria Research Foundation database (http://www.
progeriaresearch.org/prf-by-the-numbersprf.html), there are an estimated 
200–250 children living with progeria worldwide at any one time, and 103 of them 
have been identified as of April 2013. Progeria affects both sexes and all races, and 
HGPS cases have been discovered in over 40 different countries. In particular, a map 
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of ascertained HGPS children is available at the Progeria 
Research Foundation portal (http://www.findtheother150.
org/), and there are records of 20 cases in Northern America, 
16 cases in Central and Southern America, 24 cases in Europe 
and the Mediterranean regions, four cases in Africa, and 
18 cases in Asia.
The disease was named after the reports by Jonathan 
Hutchinson and Hastings Gilford, the doctors who first 
described it in England, and it is classified as a segmental 
progeroid syndrome since multiple organs and tissues repli-
cate phenotypes associated with normal aging.3,4
Children with HGPS appear healthy at birth but develop 
distinctive clinical features during the first years of their 
life, including severe growth retardation, usually associated 
with skeletal alteration as well as loss of subcutaneous fat 
and skin appendages, and some developmental processes are 
delayed (dentition) or absent.4 Death occurs in those affected 
by their early teenage years, and usually results from heart 
attacks and strokes.1
The majority of classical HGPS is caused by a de novo 
point mutation in exon 11 of the LMNA gene (c.1824C.T, 
p.G608G).5 The LMNA gene encodes A-type lamins, which 
are intermediate filament proteins of the inner nuclear lamina. 
The c.1824C.T mutation results in the activation of a cryptic 
splice donor site that removes 150 nucleotides from exon 11. 
The resulting lamin A∆150 messenger ribonucleic acid gives 
rise to a lamin A isoform containing an internal deletion of 
50 amino acids, known as progerin (a protein that cannot 
undergo complete maturation).5 Lamins constitute the major 
component of the nuclear lamina; in addition to providing 
structure and shape to the nucleus, they are involved in 
organizing several processes including chromatin organiza-
tion, deoxyribonucleic acid (DNA) replication, transcrip-
tion, DNA methylation and epigenetic regulation, and DNA 
repair.6 Those mechanisms are impaired in HGPS and might 
contribute to the progeria phenotype. Indeed, cells obtained 
from HGPS patients show a markedly reduced lifespan when 
grown in culture, and accumulate defects in nuclear structure 
and architecture with cell passaging, including lobulation 
of the nuclear envelope, thickening of the nuclear lamina, 
loss of peripheral heterochromatin, and clustering of nuclear 
pores, which are accompanied by an increase in the amount 
of progerin within the cells.7
HGPS-associated symptoms
A visible vein across the nasal bridge is often the first observ-
able sign in HGPS infants. A profound failure to thrive occurs 
during the first year, usually from 6 months to 12 months. 
On average, HGPS children gain 0.4–0.5 kg/year and reach a 
final weight of about 14–15 kg and a final height of 110 cm. 
Progressive alopecia usually takes place within 6 months to 
2 years, and between the ages of 2 years and 3 years, most 
children become bald.8 Other symptoms become apparent 
during the first year to third year, including characteristic 
facies, loss of subcutaneous fat, stiffness of joints, bone 
changes, and abnormal tightness of the skin over the abdo-
men and upper thighs.1 With time, the skin becomes thin, 
dry, and atrophic, with reduced turgor and sometimes with 
hyperkeratosis. Small, light-brown spots frequently develop 
on the neck and upper thorax, and subsequently on the scalp 
and limbs. Typical facial abnormalities include a receding 
mandible, a small and beaked nose, prominent scalp veins, 
prominent eyes, and protruding ears that lack lobules. The 
facial characteristics gradually develop and both the face 
and body change with time: the subcutaneous fat in the face 
disappears completely and the facial muscles decrease in 
size. The body shows increasing loss of subcutaneous fat and 
muscle bulk and the joints protrude.1,8,9 At the bone level, 
patients show clavicular hypoplasia, generalized osteopenia, 
and acroosteolyses of distal phalanges. Motor and mental 
development is normal, cognitive functions are preserved, 
and the children follow a normal psychosocial development 
and show normal behaviors for their age.1,9 Dentition is 
delayed and crowded.9 HGPS individuals have a high-pitched 
voice, do not reproduce, and their appearance becomes like 
that of an older person with time.1,8
Additional findings that are present in some but not all 
affected individuals include excessive ocular tearing, pho-
tophobia, exposure keratitis, and Raynaud’s phenomenon.9 
Most children die in their early teens from heart attacks and 
strokes caused by progressive atherosclerotic disease, with 
myocardial infarction representing the most frequent cause 
of death at a mean age of around 13 years.8 A comprehensive 
description of most of the HGPS-associated manifestations 
is provided in the following sections.
Cardiovascular disease in HGPS
Cardiovascular disease (CVD) represents the principal factor 
affecting mortality in HGPS individuals, with death resulting 
from myocardial infarction, stroke, or congestive cardiac 
failure in 75% of cases.10 Cardiovascular problems are absent 
during the first 5 years of life, but children gradually develop 
shortness of breath with exertion and easy fatigability from 
the age of 6–8 years.10 Accelerated CVD leads to debilitating 
morbidity in HGPS and culminates in mortality from myocar-
dial infarction or stroke at an average age of 13 years.11
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The rapid progression of CVD in HGPS presents an 
opportunity to explore the natural history of human CVD, 
and a study performed on 26 HGPS patients and 22 matched 
controls revealed that the carotid–femoral pulse wave veloc-
ity was dramatically elevated in patients.11 Carotid duplex 
ultrasound echobrightness, assessed as a measure of arterial 
wall density, was significantly greater than age- and sex-
matched controls in the intima–media, near adventitia, and 
deep adventitia, as was internal carotid artery mean flow 
velocity.11 Overall, those data demonstrated that, along with 
peripheral vascular occlusive disease, accelerated vascular 
stiffening is an early and pervasive mechanism of vascular 
disease in HGPS.11
Autopsy data have shown widespread atherosclerosis 
in HGPS patients. Particularly, advanced coronary athero-
sclerotic lesions have been reported, and the arteries were 
frequently stenosed or occluded by plaques or narrowing of 
intramural arteries. Occlusion of the right coronary artery, 
lesions of the left anterior descending artery, and severe 
atherosclerosis of the aorta, represent common findings in 
HGPS.10 Valvular changes and pulmonary arterial lesions 
have also been reported in HGPS individuals.10
Cerebrovascular disease in HGPS
Cerebrovascular arteriopathy and stroke have been recently 
assessed by means of a neurovascular imaging cohort study 
of HGPS, a study aimed to identify the neurovascular fea-
tures, infarct type, topography, and natural history of stroke.12 
A total of 25 children with confirmed diagnoses of HGPS 
were included in the study, which revealed a vasculopathy 
unique to HGPS, including distinctive intracranial stenooc-
clusive arterial lesions, basal cistern collateral vessels, 
and slow compensatory collateral flow over the cerebral 
convexities. Moreover, the authors identified early and 
clinically silent strokes as a prevalent disease characteristic 
in HGPS. Indeed, a radiographic evidence of infarction was 
found in 60% of patients, of which half were likely clini-
cally silent.12
Skeletal abnormalities in HGPS
A recent study performed with an inducible and tissue- specific 
mouse model, which expresses the most common HGPS 
mutation (c.1824C.T) in osteoblasts and odontoblasts, 
revealed that the expression of the HGPS mutation during 
osteoblast development results in a loss of osteocytes, irregu-
lar mineralization, and poor biomechanical properties.13
A comprehensive survey of the skeletal dysmorphisms 
observed in children with HGPS using conventional 
radiography was obtained from 39 children with the classic 
HGPS genotype, representing approximately 15%–20% 
of the world’s HGPS population.14 Small clavicles were 
observed in 100% of the patients; followed by coxa valga and 
acroosteolysis, which were observed in more than 90% of 
the patients; and resorption of the distal clavicles and narrow 
apices, both present in 82% of the subjects. Other frequent 
skeletal abnormalities were hip dysplasia (69%) and thin 
ribs (59%). In addition, 30% to 45% of the patients showed 
resorption of the anterior ribs, closed sagittal suture, general-
ized osteopenia, focal cortical defects, flexed fingers, ulnar 
minus variant, or enlarged heart. Less frequent (20%–30%) 
were dystrophic calcification, sagittal suture diastasis, 
enlarged femoral head, pseudoarthrosis, enlarged femoral 
greater trochanter, and avascular necrosis of the proximal 
femur. Kyphoscoliosis, enlarged humoral head, narrowed 
humoral diaphysis, prominent pulmonary vessels, and worm-
ian bones were reported in less than 15% of the patients, 
and other abnormalities, such as accentuated osteopenia of 
proximal humoral/femoral epiphysis, rib fracture, Madelung 
deformity, ivory epiphyses, bifid rib, and congenitally fused 
ribs were reported in 10% or less of the patients.14
Craniofacial abnormalities in HGPS
Using the Progeria Research Foundation medical and 
research database (http://www.progeriaresearch.org/
medical_database.html), data on 25 HGPS patients have been 
examined in order to provide an overview of the craniofacial 
abnormalities in progeria.15
Concerning scalp, calvarial, and skull base features, thin-
ning of the calvarium was seen in 95% of the individuals, 
often accompanied by a paucity of scalp fat (91%). A mottled 
appearance of the skull was seen in 59% of the patients. Two 
individuals (8%) had skull fractures, and prominent vascular 
markings of the bony calvaria were observed in 90% of the 
subjects. Craniofacial disproportion (a large cranium rela-
tive to the facial size), and a J-shaped sella were observed 
in almost 90% of the patients, and a delayed closure of the 
anterior fontanel was seen in 56% of them.15
Concerning oral maxillary, zygomatic arch, and parotid 
gland features, the authors observed a short mandibular ramus 
in 83% of the patients, with a gracile thin zygomatic arch in 
50% of them. A shallow glenoid fossa with a hypoplastic or 
absent articular eminence and flattening of the mandibular 
condyle were seen in 43% of the patients. Moreover, 45% 
of the children had a V-shaped palate, and 50% of them had 
disorganized dentition. A prominent parotid gland was seen 
in all the children analyzed.15
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With regard to orbital features, hypotelorism was noted 
in 86% of the children, and kinking of the optic nerves was 
seen in 89%.15
Other manifestations in HGPS
Fifteen patients with HGPS have been enrolled in a 
prospective study to evaluate otologic and audiologic 
manifestations.16 All patients had stiff auricular cartilages, 
small or absent lobules, and hypoplasia of the lateral soft-
tissue portion of the external ear canal leading to a short-
ened canal. A low-frequency conductive hearing loss in the 
250 Hz to 500 Hz range was observed in 86.4% of the ears, 
despite largely normal tympanometry.16 In addition, 71% of 
the patients had dry cerumen impaction, and 29% of them 
reported a history of recurrent otitis media.16
Insulin resistance occurs in about 50% of affected patients 
without progression to diabetes mellitus.9 A rare case of a 
10-year-old boy with genetically confirmed classical HGPS 
and hypoparathyroidism has been reported.17 Differently 
from other premature aging syndromes, such as WS or others 
caused by mutations of DNA repair genes, there is no reported 
increase of cancer incidence in HGPS patients.8,18 Cataracts 
are not frequent.8 We recently reviewed neurodegenerative 
signs or symptoms in premature aging disorders, and they 
are absent in HGPS individuals.1
From mild to severe progeria:  
the genetic basis of classical HGPS  
and atypical progeria syndromes
Although the majority (approximately 90%) of classical 
HGPS is caused by a de novo point mutation in exon 11 of 
the LMNA gene (c.1824C.T, p.G608G), it was clear from 
the beginning that other mutations in LMNA could cause a 
similar phenotype.5 Particularly, the genetic basis of HGPS 
was identified in 2003 by two independent research groups.5,19 
Eriksson et al5 observed the G608G mutation in 90% of 20 
HGPS individuals, and De Sandre- Giovannoli et al19 observed 
it in two affected children. A patient with a c.1822G.A 
mutation (p.G608S), with classical HGPS, was also recorded 
by Eriksson et al.5
The LMNA gene encodes the four different A-type lamins 
(lamin A, lamin A∆10, lamin C, and lamin C2), which are 
intermediate filament proteins of the inner nuclear lamina.1 
Lamin A (encoded by exons 1–12) and lamin C (encoded by 
exons 1–10) are the major proteins expressed in differenti-
ated cells. Lamin A∆10 is identical to lamin A except that it 
lacks exon 10 and has been detected in cells from colon and 
placenta, in leukocytes and fibroblasts, and in tumor cells. 
Lamin C2 has an alternative exon 1 compared with lamin 
C and is present in germ cells.1 Lamin A proteins contain 
CaaX boxes at their C-terminal ends; they are synthesized as 
prelamin A proteins, which undergo farnesylation and other 
posttranslational modifications to become mature proteins 
(Figure 1).
The p.G608G mutation results in the activation of a cryp-
tic splice donor site, leading to the production of a lamin A 
isoform containing an internal deletion of 50 amino acids, 
known as progerin – a protein that cannot undergo complete 
maturation.5 Particularly, the deletion eliminates the site for 
endoproteolitic cleavage by zinc metalloproteinase Ste24 
homolog (ZMPSTE24), a cleavage required for the produc-
tion of mature lamin A. The recurrent c.1824C.T mutation 
causing HGPS is a de novo dominant point mutation, mostly 
originating on the paternal allele and often linked with 
advanced paternal age.5
The zinc metalloprotease, ZMPSTE24, plays a critical 
role in nuclear lamin biology by cleaving the prenylated and 
carboxylmethylated 15-amino acid tail from the C-terminus 
of prelamin A to yield mature lamin A (Figure 1). Two 
patients with extraordinarily severe forms of progeria caused 
by unusual mutations in LMNA have been described.20 Both 
mutations (IVS11+1G.A and p.V607V) resulted in a strong 
activation of the aberrant splice site observed in typical 
HGPS, leading to increased progerin expression compared 
to typical HGPS cases.20 By contrast, two subjects bearing 
a missense (p.T623S) mutation leading to the deletion of 
35 amino acids in exon 11 of LMNA showed a less aggres-
sive progeroid phenotype (slowly progressing progeria) 
compared to classical HGPS.21,22 Overall, the amount of 
toxic progerin in cells appears to correlate with the severity 
of disease outcomes.20
Interestingly, recessive mutations in ZMPSTE24 also 
disrupt lamin A proteolytic processing and are associated 
with three distinct but related human diseases that share 
features of premature aging, with a gradation of severity.23 
Indeed, ZMPSTE24 mutations cause: (1) the mild prog-
eroid disorder mandibuloacral dysplasia, a rare autosomal 
recessive disorder characterized by postnatal growth retar-
dation, craniofacial anomalies, skeletal malformations, 
and mottled cutaneous pigmentation; (2) a severe form 
of progeria denoted as atypical HGPS; and (3) restrictive 
dermopathy (RD), a fatal neonatal disorder characterized 
by severe intrauterine growth delay that can be considered 
as an “extreme form” of premature aging.23 Twenty human 
ZMPSTE24 alleles have been identified that are associated 
with those diseases. They have been recently reviewed by 
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Barrowman et al,24 who demonstrated a correlation between 
decreasing ZMPSTE24 protease activity and increasing 
disease severity. Particularly, complete loss-of-function 
alleles are associated with RD, whereas retention of partial, 
measurable activity results in mandibuloacral dysplasia or 
severe progeria.23 Figure 1 illustrates most of the known 
LMNA and ZMPSTE24 mutations linked to progeroid 
diseases.
Although the mechanism whereby persistently farnesy-
lated lamin A, either resulting from LMNA or ZMPSTE24 
mutations, causes premature aging phenotypes is unknown, 
changes in chromatin architecture and in histone methylation 
and gene expression, defective DNA repair and accumulation 
of DNA damage, impaired structural and mechanical prop-
erties of the nuclear lamina, and perturbations in transcrip-
tion factors and nuclear proteins, are among the suggested 
pathologic mechanisms.1,8
The diagnosis of HGPS is based on the recognition of 
common clinical features and the detection of either the 
c.1824C.T (p.G608G) heterozygous LMNA mutation in the 
classic form of HGPS, or one of three of the heterozygous 
LMNA mutations in atypical HGPS: c.1822G.A (p.G608S), 
c.1821G.A (p.V607V), or c.1968+1G.A (IVS11+1G.A) 
(Figure 1).9 Noteworthy, several patients with atypical 
progeroid syndromes, which have been referred to as 
atypical progeroid syndromes (also called atypical HGPS, 
nonclassical progeria, or atypical WS), do not carry LMNA 
splicing mutations, but other heterozygous, homozygous, or 
compound heterozygous mutations in the LMNA gene.24 The 
clinical features of those patients include growth retardation 
and involve the same body systems (bones, body fat, skin, 
and hair) as in classical HGPS, but the course and severity 
of the symptoms vary. The patients have differing ages of 
onset and symptom severity, with some nearly as severe as 
s
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Figure 1 Representation of prelamin A processing and summary of LMNA and ZMPSTE24 mutations leading to classical and atypical progeria.
Notes: Prelamin A requires maturation to become mature lamin A. First, the C-terminal end of prelamin A contains a CaaX motif, which is modified by farnesylation of the 
cysteine residue (1), mediated by a FTASe protein, and is followed by the cleavage of the (2) –aaX terminal residues that can be performed either by RCe1 or by ZMPSTe24. 
(3) After the cleavage, the cysteine residue is carboxymethylated by ICMT. The last step removes the C-terminal 15 residues through cleavage by (4) ZMPSTe24, yielding 
mature lamin A. In HGPS cells bearing the common LMNA p.G608G mutation, the activation of the cryptic splice site results in the deletion of a 50aa region from prelamin 
A (indicated in dark blue in the figure), which contains the ZMPSTe24 cleavage site (indicated in the figure). As a result, the p.G608G mutation leads to the production and 
the accumulation of a smaller prelamin A protein, which cannot undergo complete maturation, termed progerin. A diagnostic test is available for the common p.G608G 
mutation, as well as for the less common LMNA splicing mutations, namely p.G608S, p.v607v, or IvS11+1G.A, all resulting in the activation of the cryptic splice site. 
Several other LMNA mutations have been reported in a small number of patients and these lead to a spectrum of progeroid phenotypes ranging from mild–moderate to 
very aggressive forms, and are referred to as atypical progeroid syndromes. Those mutations can be either dominant (in red ink) or recessive (in green ink) and can alter 
residues throughout the protein structure with no clear clustering in a single region of lamin A. The term (ch) indicates a compound heterozygous mutation (in orange ink). 
Underlined LMNA mutations are those observed in atypical wS cases. Recessive ZMPSTE24 mutations also disrupt prelamin A processing and are associated with three 
distinct, but related, human diseases that share features of premature aging, with a gradation of severity: mandibuloacral dysplasia, atypical HGPS, and restrictive dermopathy. 
Concerning ZMPSTE24 mutations, the term (ch) indicates a compound heterozygous mutation (in orange ink), otherwise the mutation was found in homozygosis in the 
patient (in green ink).
Abbreviations: HGPS, Hutchinson–Gilford Progeria Syndrome; ZMPSTe24, zinc metalloprotease related to Ste24p; FTASe, farnesyltransferase; RCe1, Ras-converting 
enzyme 1; ICMT, isoprenylcysteine carboxyl methyltransferase; wS, werner syndrome.
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HGPS, others (such as p.R435C) leading to atypically mild 
RD, but most are far less severe.24 For example, patients 
affected by atypical WS have early onset of aging phenotypes 
and an accelerated rate of disease progression than typi-
cal WS individuals; they also commonly show absence of 
bilateral cataracts and diabetes, which are common features 
in typical WS.25 Over 20 LMNA mutations causing atypical 
progeroid syndromes have been discovered and have been 
recently reviewed by Doubaj et al;23 these are summarized 
in Figure 1.
In this regard, a dominantly inherited premature aging 
syndrome that includes prominent cardiovascular and 
cutaneous manifestations, called LMNA-associated car-
diocutaneous progeria syndrome, was recently described.26 
The disease showed a later onset than classical HGPS, with 
skin manifestations of aging appearing in the third decade 
of life. Affected individuals also developed CVD leading to 
death in their fourth decade. One affected individual in this 
family also showed primary malignancies not previously 
reported in LMNA-linked progeria disorders. This atypical 
progeroid syndrome was caused by a novel LMNA muta-
tion (c.899A.G, p.D300G) leading to abnormalities of the 
nuclear membrane architecture.26
There is also indication from studies in nonagenarians 
suggesting that common LMNA polymorphisms and haplo-
types may play a role in the human lifespan.27 In this regard, 
Rodríguez and Eriksson28 have recently observed that an 
LMNA single nucleotide polymorphism (rs4641) results in 
low and high expressing alleles of the LMNA gene, and might 
account for the variability in phenotype seen among HGPS 
individuals.28 Noteworthy, not all LMNA mutations cause 
progeria. More than 450 mutations of the gene have been 
described causing several different autosomal dominant or 
recessive diseases collectively called primary laminopathies, 
and these include muscular dystrophies, lipodystrophies, 
neuropathies, cardiomyopathies, and the above-discussed 
segmental progeroid syndromes.26,29
Werner syndrome
WS is a rare autosomal recessive disorder also called adult 
progeria, and represents the most studied disease model of 
premature aging in adulthood.30 In the Japanese population, 
a founder effect has been described, and the frequency of WS 
has been roughly estimated to be 1:100,000.30 Another cluster 
of WS has been identified in Sardinia, with 18 described cases 
due to a founder effect.31 The prevalence of heterozygous 
carriers in Japan is approximately 1/167, and it is estimated 
to be approximately 1/120 in Sardinia.31 Outside of Japan 
the disease prevalence is estimated to be approximately 
1:1,000,000–1:10,000,000.30
The syndrome was first described in the doctoral thesis of 
Werner32 in 1904. According to a recent report, 1,487 WS cases 
have been recorded from 1904 to the end of 2008 – 1,128 in 
Japan and 359 outside Japan.33 The patients develop features 
reminiscent of premature aging beginning in the second decade 
of life, including grey hair, alopecia, prematurely aged face 
with beaked nose, skin atrophy with scleroderma-like lesions, 
ischemic heart disease, osteoporosis, bilateral cataracts, type 2 
diabetes mellitus, lipodystrophy, and hypogonadism. They also 
experience an increased risk of cancers, and in most cases, they 
die because of malignant tumors or arteriosclerosis during the 
fourth and fifth decades of life.30
The disease is caused by mutations of the WRN gene, 
which encodes the WRN protein, a member of the RecQ DNA 
helicase family.34 WRN is a multifunctional nuclear protein 
that maintains genome stability by means of DNA-dependent 
adenosine triphosphatase (ATPase), 3′→5′ helicase, 3′→5′ 
exonuclease, and DNA strand annealing activities.35 Most 
of the WRN mutations result in the production of truncated 
proteins lacking the nuclear localization signal, with the 
subsequent absence of functional WRN protein in nuclei.36 
WRN has several functional domains and is considered to be 
a “caretaker of the genome” since it participates in distinct 
DNA metabolic pathways, including DNA replication, DNA 
recombination, telomere maintenance, apoptosis, and DNA 
repair.36 Cells isolated from WS individuals display increased 
chromosomal aberrations and premature senescence in cul-
ture, as well as accelerated telomere shortening and several 
defects in DNA replication.37
In 20% of cases, WS is not caused by WRN gene muta-
tions, but often by mutations in the LMNA gene.25 As 
discussed in the previous section of this paper, WS caused 
by LMNA mutations is referred to as atypical Werner’s 
syndrome.25
wS-associated symptoms
The lack of a pubertal growth spurt during the teen years is 
the first clinical sign in WS individuals, leading to a charac-
teristic short stature and low bodyweight. A recent analysis 
of 196 WS Japanese cases reported that mean height and 
bodyweight were 158.3 cm and 45.3 kg for male patients, and 
148.5 cm and 37.7 kg for female patients, respectively.38 In 
their 20s and 30s, WS individuals begin to manifest alopecia, 
greying hair, and scleroderma-like skin changes, followed by 
bilateral cataracts, type 2 diabetes mellitus, hypogonadism, 
skin ulcers, and osteoporosis.1
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A recent epidemiological study of 196 cases revealed 
that greying or loss of hair, bird-like faces, cataracts, and 
skin atrophy were present in 93% to 99%.38 Other common 
features were clavus or callus, skin ulcers, flat foot, abnor-
mality of the voice, and calcification in the Achilles tendon, 
observed in 80%–90% of the subjects.38 Similarly, a trend 
analysis in Japanese WS individuals revealed that bird-like 
faces and a stocky trunk with extremely thin extremities are 
still a hallmark of the disease, but the body size, which is 
also still small, has been expanding in recent years, in con-
cert with the growing constitution of the general Japanese 
population, and some patients exceeded 177 cm in height 
and weighed over 70 kg.33
Abnormal glucose and lipid metabolism, hypogonad-
ism, and bone deformity appear by the fourth decade of life 
in WS subjects.38 Impaired glucose tolerance is reported in 
15%–20% of WS subjects, diabetes mellitus in 55%–70%, 
and dyslipidemia in 60%–85%.38 Fertility in WS patients 
appears to decline soon after sexual maturity, and hypogonad-
ism has been reported in 40% of both sexes.38 Osteoporosis 
was observed in more than 60% of WS cases, while osteoar-
thritis has not been frequently reported in WS.33,38
For several years, the clinical diagnosis of WS was 
based on the presence of four cardinal signs (cataracts, skin 
changes, short stature, and greying or loss of hair), which 
are observable in more than 95% of the cases, as well as on 
additional signs (osteoporosis, voice change, atheroscle-
rosis, type 2 diabetes mellitus, and so on). For a definite 
diagnosis, all the cardinal signs (onset over 10 years old) 
and two additional signs should have been present. In addi-
tion, sequencing of the WRN gene could be performed, and 
the absence of normal WRN protein would be confirmed by 
Western blot analysis.4,35
Following more recent observations, revised diagnostic 
criteria have been proposed,38 including the following cardi-
nal signs and symptoms (onset over 10 years until 40 years 
of age): (1) progeroid changes of the hair (gray hair, bald-
ness, and so on); (2) cataracts (bilateral); (3) changes of the 
skin (atrophic skin, tight skin, clavus, callus); (4) soft-tissue 
calcification (Achilles tendon, and so on); (5) bird-like face; 
and (6) abnormal voice (high-pitched, squeaky, hoarse). 
Additional signs include abnormal glucose and/or lipid 
metabolism, deformation and abnormality of the bone (osteo-
porosis, and so on), malignant tumors, parental consanguin-
ity, premature atherosclerosis, hypogonadism, short stature, 
and low bodyweight. The diagnosis is confirmed if all the 
cardinal signs are present, or if there is a gene mutation in 
addition to at least three cardinal signs, and suspected if two 
or more cardinal signs are present, or if 1–2 cardinal signs 
in addition to other signs, are present.38
An unusual spectrum of cancers has been observed in 
WS subjects who usually die at a mean age of 53–54 years 
from cancer or arteriosclerosis.30 Controversy exists regard-
ing the degree of brain involvement in WS.1 A discussion of 
recent reports of cancer, atherosclerosis, and nervous system 
disorders in WS will be provided in the following sections.
Atherosclerosis and cancer in wS
Complications caused by atherosclerosis and cancer represent 
the major cause of death in WS subjects.  Arteriosclerosis 
obliterans has been observed in more than 20% of WS 
 subjects, and coronary heart disease in 11%–16% of them.38 
Less frequent are cerebral hemorrhage and cerebral infarc-
tion, observed in 2%–5% of cases.38 According to recent 
trend analyses, atherosclerosis in WS subjects might result 
from either abnormal lipid metabolism, or from inflamma-
tory mechanisms.33
Concerning the cancer incidence in WS individuals, 
339 (23%) out of the 1,487 WS cases described up to the 
end of 2008 were diagnosed with cancer,33 and a nationwide 
epidemiological study carried out in Japan from 2009 to 
2011 revealed that cancer occurred in more than 40% of the 
196 analyzed WS cases.38 Cancer in WS individuals often 
manifests with early age of onset, a high frequency of specific 
tumor types, including uncommon tumor types and unusual 
tumor sites, and with the presence of multiple tumors in 
individual patients.39
Lauper et al39 have recently provided a detailed and 
quantitatively rigorous view of cancer type and associated 
type-specific risk in WS. Frequent neoplasms included: 
thyroid neoplasms (16.1%), malignant melanoma (13.3%), 
meningioma (10.9%), soft tissue sarcomas (10.1%), hemato-
logic/lymphoid cancers (9.3%), and osteosarcomas (7.7%). 
Other cancers, including nonmelanoma skin cancer, gastro-
intestinal cancer, ovarian cancer, genitourinary tract cancers, 
hepatobiliary cancer, head and neck carcinomas, and breast 
cancer, were observed in 3%–5% of the cases. Less frequent 
cancers (1%–2%) were those of the lung and central nervous 
system, as well as adrenocortical carcinomas.39 A trend 
analysis in Japan revealed that the average age of onset of 
malignancy in WS increased from 37 years old in 1966 to 
49 years old in 2008.33
Nervous system disorders in wS
We recently reviewed neurological abnormalities in pre-
mature aging disorders, and they are not constant findings 
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in WS.1 Brain atrophy has been observed in 40% of WS 
patients, but only a few cases of dementia or peripheral 
neuropathy have been reported. A few cases of dementia 
have been recorded, but the analysis of amyloid beta pep-
tide and hyperphosphorylated tau protein (the hallmarks of 
Alzheimer’s dementia) revealed that WS individuals do not 
usually appear to be susceptible to Alzheimer’s disease.1 
Myelopathy, demyelinization, and associated central and/
or peripheral neuropathy have been described in at least six 
patients.40–44 Schizophrenia of the paranoia type was also 
recorded in about 10% of patients.33
Genetics of wS
Typical WS is an autosomal recessive genetic disease. 
Therefore, the parents of a proband are obligate heterozy-
gotes for a disease-causing mutation, and at conception each 
sibling of an affected individual has a 25% chance of being 
affected and a 50% chance of being an asymptomatic carrier. 
Classical WS is caused by mutations of the WRN gene on 
chromosome 8. The locus spans approximately 250 kb and 
consists of 35 exons.34
More than 70 WRN gene mutations have been found in WS 
patients; these are mainly nonsense mutations, insertions, and/
or deletions, as well as splice mutations resulting in the pro-
duction of truncated proteins lacking the nuclear localization 
signal, with subsequent absence of functional WRN protein in 
nuclei.36,45 The WRN protein has several functional domains 
(Figure 2), and mutations leading to WS have been observed 
in all of them. There are founder mutations reported among 
Japanese patients (c.3139-1G.C, which results in skipping 
of exon 26) and in Sardinian patients (c.2089-3024A.G, 
which creates a new exon between exons 18 and 19).30,31 
Potential founder mutations have been reported for Dutch 
(c.3590delA, p.N1197fs), Turkish (c.3460-2A.G, exon 30 
deletion), and Moroccan (c.2179dupT, p.C727fs) patients.36 
The most common mutation in Caucasians is a stop codon 
mutation in exon 9 (c.1105C.T, p.R369X), accounting for 
approximately 20% of the mutations.45 Genetic screening 
combined with Western blot analysis are performed as routine 
diagnostic tests, and Figure 2 shows the most frequent muta-
tions observed by ethnic group.
Conclusion
Advancements in our understanding of the genetic and 
molecular basis of premature aging disorders have led to 
a better understanding of the onset and progression of the 
clinical manifestations. They include, for example, the recent 
discovery of high- and low-expressing LMNA alleles that 
might account for the different phenotypes observed in HGPS 
patients, a better characterization of the mutations leading to 
impaired or completely absent ZMPSTE24 protein activity, 
or those in the LMNA gene leading to atypical HGPS, overall 
accounting for a spectrum of disorders ranging from neonatal 
progeria to atypical WS.20–28
In parallel, the advancements in diagnostic examination 
techniques, and the creation of disease registers or databases 
allowing large case–control epidemiological studies in both 
HGPS and WS patients, have led to a better understanding of 
the epidemiology of disease-associated signs and symptoms. 
This has led, for example, to a proposed revision of the clini-
cal diagnostic criteria for WS, to the discovery that cerebral 
infarctions in HGPS are more frequent than expected, and 
N
Exonuclease
WRN protein
Helicase RQC HRDC
NLS C
Common WRN gene mutations
Japanese population (founder effect): c.3139-1G>C → skipping of exon 26
Sardinian population (founder effect): c.2089-3024A>G → new exon between exons 18 and 19
Turkish population (suspected founder effect): c.3460-2A>G → deletion of exon 30
Caucasians (common mutation): c.1105C>T → p.R369X: stop codon mutation in exon 9
Moroccan population (suspected founder effect): c.2179dupT → p.C727fs
Dutch population (suspected founder effect): c.3590delA → p.N1197fs
Figure 2 Representation of the wRN protein and summary of the most common WRN mutations leading to werner syndrome.
Notes: The diagram illustrates the functional domains of the wRN protein: exonuclease, helicase, RQC, HRDC, and the NLS. Over 70 insertion/deletion mutations, 
missense and nonsense mutations, as well as splice mutations have been found in the different domains of the wRN protein. Genetic screening is performed as routine 
diagnostic tests, and the figure shows the most frequent mutations observed according to ethnic group.
Abbreviations: RQC, RecQ C-terminal domain; HRDC, helicase and RNase D C-terminal domain; NLS, nuclear localization signal; N, amino terminal; C, carboxyl terminal.
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to a better understanding of cancer incidence in WS, among 
others.12,38,39
Treatments for HGPS and WS are only available for the 
symptoms rather than for the disease itself. For example, 
aggressive treatment of skin ulcers, cholesterol-lowering 
drugs if the lipid profile is abnormal, control of type 2 
 diabetes mellitus, surgical treatment of cataracts, and treat-
ment of malignancies in a standard fashion are among the 
available medicaments in WS, which are often accompanied 
by dietary/physical regimens to reduce atherosclerosis risk.1
Similarly, drugs, dietary changes, and exercise are 
recommended for HGPS individuals to counteract athero-
sclerosis risk, body fat reduction, and atrophy of muscles.1 
Interestingly, the results of the first clinical trial in HGPS 
revealed that lonafarnib, a farnesyltransferase inhibitor, 
resulted in better hearing, improved bone structure, and led 
to gaining additional weight and/or to increased flexibility 
of the blood vessels.46 In this regard, recent trend analyses 
in Japanese WS patients are extremely important,33 as they 
showed a delayed onset of typical progeroid phenotypes in 
WS, which may be explained by the environmental changes 
including lifestyle and medical improvements, thereby offer-
ing a potential for interventional trials.
It is clear from that survey that, in recent years, there 
has been a trend toward an increase in body size in WS 
patients, as well as a delayed average age at onset of malig-
nancies that follow the rapid improvement and changes in 
the average lifespan and lifestyle in the general popula-
tion all over the world.33 The future will be to combine 
genetic, diagnostic, and epidemiological data in order to 
clarify several of these gene–environment interactions and 
their relevance to the onset of disease-related symptoms. 
In addition, as recently shown by some authors studying 
HGPS patients,28 a deeper characterization of the genetics 
of prematurely aged individuals might help to explain and 
predict the onset and progression of some of the symptoms, 
since several of these symptoms might result from the 
combined presence of different mutations in the same or 
different genes, thereby opening a window for personal-
ized interventions.
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